The results showed that low expression of BDH2 was positively associated with the TNM stage, depth of invasion, and lymph node metastasis, but not with other clinicopathological features including gender, age, differentiation, tumour localization, or tumour size. This evidence concerns the gene BDH2 and metastatic malignant neoplasm in the lymph nodes.